公开(公告)号：US11377491B2

公开(公告)日：2022-07-05

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene Liao ,  Qiang Liu ,  Zhiqiang An ,  Ningyan Zhang ,  Xun Gui ,  Chengcheng Zhang ,  Mi Deng ,  Jingjing Xie

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

公开(公告)号：US11365250B2

公开(公告)日：2022-06-21

申请号：US16767152

申请日：2018-11-29

Applicant: The Board of Regents of The University of Texas System

Inventor： Bruce Beutler ,  Evan Nair-Gill ,  Xue Zhong ,  Jinglei Zhang ,  Pingping Wang

IPC: C07K16/28

Abstract: The present disclosure generally relates to compositions and methods for cancer immunotherapy, as well as hematopoietic recovery following cancer treatment such as chemotherapy or irradiation.

公开(公告)号：US11326263B2

公开(公告)日：2022-05-10

申请号：US16353183

申请日：2019-03-14

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Brian Dennis ,  Krishnan Rajeshwar ,  Norma Tacconi ,  Wilaiwan Chanmanee ,  Homayon Homayoni ,  Ghazaleh Ghadimkhani

IPC: C25B3/25 ,  B01J23/72 ,  B01J37/34 ,  B01J35/00 ,  B01J35/02 ,  H01M14/00 ,  C25B11/051 ,  C25B11/057 ,  C25B11/091 ,  C25B13/08 ,  C25B15/08 ,  H01G9/20 ,  B01D69/02 ,  B01D69/12 ,  B01D71/02 ,  B01D71/36 ,  B01D71/80

Abstract: The present disclosure relates to nanocomposites of CuO/Cu2O and continuous flow solar reactors. The nanocomposites can be utilized as a photocatalyst and can be incorporated into photoelectrochemical devices. The described devices, systems, and methods can be used for converting CO2 into one or more alcohols and other small organics with the use of solar energy and electricity. Other embodiments are described.

公开(公告)号：US20220111249A1

公开(公告)日：2022-04-14

申请号：US17498986

申请日：2021-10-12

Applicant: The Board of Regents of the University of Texas System ,  The University of Alabama

Inventor： David A. Brown ,  Chih-Ying Li ,  Mansoo Ko ,  Shengting Cao ,  Xuefeng Wang ,  Fei Hu ,  Yu Gan ,  Liang Zhang

IPC: A63B22/02 ,  A63B24/00

Abstract: The present disclosure presents improved treadmill control systems and methods. One such method comprises initiating a recording a video sequence of a walking exercise by a subject on a treadmill device; extracting intra-gait phases of the subject from the recorded video sequence using a video temporal alignment with a neural network; generating a series of treadmill belt control settings for the treadmill device corresponding to each phase of the gait pattern of the subject; and signaling the series of treadmill belt control settings to a motor controller of the treadmill device. Other methods and systems are also provided.

公开(公告)号：US11294652B2

公开(公告)日：2022-04-05

申请号：US16385118

申请日：2019-04-16

Applicant: The Board of Regents of The University of Texas System

Inventor： Tongping Liu ,  Mohammad Mejbah ul Alam ,  Abdullah Al Muzahid

IPC: G06F9/455 ,  G06F8/41 ,  G06F9/48 ,  G06F9/52

Abstract: The techniques described herein may provide techniques to detect, categorize, and diagnose synchronization issues that provide improved performance and issue resolution. For example, in an embodiment, a method may comprise detecting occurrence of synchronization performance problems in software code, when at least some detected synchronization performance problems occur when a contention rate for software locks is low, determining a cause of the synchronization performance problems, and modifying the software code to remedy the cause of the synchronization performance problems so as to improve synchronization performance of the software code.

公开(公告)号：US11285190B2

公开(公告)日：2022-03-29

申请号：US15567762

申请日：2016-04-18

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Rui Yue

IPC: A61K38/18 ,  A61P19/08 ,  A61K38/29 ,  A61K45/06 ,  A61P35/04 ,  A61P19/10

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

公开(公告)号：US11274282B2

公开(公告)日：2022-03-15

申请号：US16875056

申请日：2020-05-15

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Sergio E. Rodriguez ,  Robert W. Cross ,  Chad E. Mire ,  Thomas W. Geisbert

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/23 ,  C12N15/00 ,  C12N15/74 ,  C12N7/00 ,  C07K14/005 ,  A61K39/205 ,  C12N15/86 ,  G01N33/569 ,  A61P31/14

Abstract: Certain embodiments are directed generally to compositions and methods related to recombinant vesicular stomatitis virus vectors (ΔGrVSV) encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (CCHFV-GPC) and forming a recombinant vesicular stomatitis virus vector encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (ΔGrVSV-CCHFV-GPC).

公开(公告)号：US20220056124A1

公开(公告)日：2022-02-24

申请号：US17273538

申请日：2019-09-05

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Dawei BU ,  Zhiqiang AN ,  Hui DENG ,  Philipp E. SCHERER

IPC: C07K16/26 ,  A61P35/00

Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

公开(公告)号：US20220000899A1

公开(公告)日：2022-01-06

申请号：US17180469

申请日：2021-02-19

Applicant: ASTROCYTE PHARMACEUTICALS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： William S. Korinek ,  James D. Lechleiter ,  Theodore E. Liston

IPC: A61K31/7076 ,  A61K31/52

Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

公开(公告)号：US20210380695A1

公开(公告)日：2021-12-09

申请号：US17322827

申请日：2021-05-17

Applicant: ImmuneSensor Therapeutics, Inc. ,  The Board of Regents of the University of Texas System

Inventor： Zhijian CHEN ,  Lijun SUN

IPC: C07K16/28 ,  A61K31/7084 ,  A61K47/68 ,  A61P35/00

Abstract: The disclosure provides, among other things, methods and uses for treating a disease or disorder, particularly a cancer, in a patient, comprising conjointly administering a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody) and a STING agonist to the patient, wherein the CTLA4 inhibitor is administered intratumorally to the patient. The STING agonist can be administered intratumorally, orally or systemically (e.g., intravenously, intramuscularly, or subcutaneously) to the patient.